Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

Next Previous
Trial Profile

A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGDM1400 (Primary) ; PGT 121 (Primary) ; TMB-380 (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 01 Jun 2022 Primary endpoint has been met (Antiviral activity of PGDM1400 in combination with PGT121 or PGDM1400 in combination with PGT121 and VRC07-523LS mAbs) , according to Results published in the Nature Medicine
  • 01 Jun 2022 Primary endpoint has been met (Impact of viral load and/or ART) , according to Results published in the Nature Medicine
  • 01 Jun 2022 Primary endpoint has been met (Area under the concentration decay curve (AUC)) , according to Results published in the Nature Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top